依那普利联合丹参酮治疗肺心病急性加重期患者

Efficiency of Combined Treatment of Enazepril and Tanshinon on Acute Exacerbation of Chronic Pulmonary Heart Disease Department of Emergency,First Affiliated Hospital of Xinxiang Medical University

目的:分析依那普利联合丹参酮在肺心病急性加重期患者治疗中的疗效,评价其安全性。方法:将新乡医学院第一附属医院收治的114例肺心病急性加重期的患者,随机分成观察组和对照组,每组各57例。对照组在临床常规治疗的基础上应用依那普利剂量治疗,观察组在对照组的基础上联合应用丹参酮进行治疗,对治疗后两组临床疗效进行评定,同时对治疗前后患者血气及血流等指标变化监测,并进行分析比较。结果:观察组与对照组的有效率分别为94.7%,80.7%,观察组显著高于对照组(P<0.05);两组患者治疗前后在血气、血流及心功能等指标均不同(P<0.05),同时观察组中患者治疗前后的指标差值明显优于对照组(P<0.05);两组不良反应情况差异无明显不同。结论:依那普利联合丹参酮治疗肺心病急性加重期的患者具疗效显著,且安全有效,不良反应可耐受,值得临床应用推广。

Objective：To discuss efficiency of combined treatment of enalapril and tanshinon on acute exacerbation of chronic pulmonary heart disease and evaluate its safety.Method： One hundred and fourteen collected patients with acute exacerbation of chronic pulmonary heart disease in hospital were randomLy divided into two groups,observation group and control group,57 patients in each group.On the basis of conventional clinical therapy,enalapril treatment was given to patients in the control group,the observation group was given tanshinon on base of the treatment in the control group,after treatment,the curative effect in the two groups were assessed,while the indicators of changes in hemorrheology in patients were monitored.Result： The observation group and control group response rate were 90.7% and 80.7%,respectively,the rate in the observation group were significantly higher than that in control group（P0.05）.Before and after treatment inindicators of blood gas,blood flow and cardiac function and others were different（P0.05） in two groups,while after treatment in observation group,the indicators were significantly better than that in control group（P0.05）;adverse reactions between the two groups had no significantly difference.Conclusion： The curative effect of combined treatment of enalapril and tanshinon medicine is significant better,and the treatment is safe.The combined application of enalapril and tanshinon should be widely recommend.